David Schwicker has biopharmaceutical consulting expertise spanning more than 25 years. He is the founder and principal of ORPHA Strategy Consulting, an independent strategy consultancy focused on the early, accelerated market authorization and market access for orphan, speciality, and advanced medicines, as well as real-world patient-centered research in rare diseases.
David's dedication to client consulting continues to evolve and has allowed him to develop a capacity for quickly grasping complex information and developing innovative strategic solutions. He has longstanding scientific experience and expert contacts has authored and co-authored numerous peer-reviewed publications and is a speaker at international meetings.
David was Vice President with PAREXEL International in the US, responsible for registries, outcomes research, market access, and expanded access programs. Since returning to Europe, David has designed and implemented observational studies including 200,000 patients. From 2007 to 2009, he served as the Managing Director of Abt Associates (Abt Bio-Pharma Solutions) in Europe.